Vivani Medical, Inc.(VANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VANI Vivani Medical, Inc.

Trading 11-13 11:16:42 EST

0.8917

-0.0917

-9.32%

High0.9871	Low0.8882	Vol93.83K
Open0.9700	D1 Closing0.9834	Amplitude10.06%
Mkt Cap80.43M	Tradable Cap33.76M	Total Shares90.20M
T/O87.14K	T/O Rate0.25%	Tradable Shares37.86M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VANI","market":"US","secType":"STK","nameCN":"Vivani Medical, Inc.","latestPrice":0.8917,"timestamp":1794586418947,"preClose":0.9834,"halted":0,"volume":93826,"delay":0,"changeRate":-0.0932479153955664,"floatShares":37857645,"shares":90203400,"eps":-0.351463,"marketStatus":"Trading","change":-0.0917,"latestTime":"11-13 11:16:42 EST","open":0.97,"high":0.9871,"low":0.8882,"amount":87142.1735336,"amplitude":0.100569,"askPrice":0.8917,"askSize":100,"bidPrice":0.8879,"bidSize":50,"shortable":0,"etf":0,"ttmEps":-0.351463,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1794603600000},"marketStatusCode":2,"adr":0,"listingDate":1416373200000,"exchange":"NASDAQ","adjPreClose":0.9834,"preHourTrading":{"tag":"盘前","latestPrice":0.987,"preClose":0.9834,"latestTime":"09:25 EST","volume":4970,"amount":4953.507055,"timestamp":1794579922009,"change":0.0036,"changeRate":0.003661,"amplitude":0.012508},"postHourTrading":{"tag":"盘后","latestPrice":0.99,"preClose":0.9834,"latestTime":"19:53 EST","volume":4819,"amount":4734.3265,"timestamp":1794531200315,"change":0.0066,"changeRate":0.006711,"amplitude":0.026032},"volumeRatio":0.82601,"impliedVol":1.6231,"impliedVolPercentile":0.7331},"requestUrl":"/m/hq/s/VANI","defaultTab":"news","newsList":[{"id":"2682599125","title":"Vivani Medical Reports no Treatment-Related Adverse Events for Semaglutide Implant in Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2682599125","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682599125?lang=en_us&edition=fundamental","pubTime":"2026-11-12 21:10","pubTimestamp":1794489056,"startTime":"0","endTime":"0","summary":"Vivani Medical Reports No Treatment-Related Adverse Events for Semaglutide Implant in Phase 1 TrialVivani Medical today reported positive top-line results from SLIM-1, a Phase 1 trial of its NPM-139 s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nNDL1VB2Ft:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4082","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","SG9999014013.SGD","LU2095319765.USD","LU2210149790.SGD","NDAQ","LU0314104364.USD","SG9999014005.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","BCDF","IE00B64PRP62.GBP","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","SG9999014039.USD","BK4112","VANI","IE00BN0W2T93.GBP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682967445","title":"Vivani Medical - no Treatment-Related Adverse Events Reported in Npm-139 Group; 5 of 10 in Wegovy Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2682967445","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682967445?lang=en_us&edition=fundamental","pubTime":"2026-11-12 21:00","pubTimestamp":1794488400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nTUA6JS4B7:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682859605","title":"Vivani Medical - to Advance Npm-139 to Phase 2 Trial in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2682859605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682859605?lang=en_us&edition=fundamental","pubTime":"2026-11-12 21:00","pubTimestamp":1794488400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nTUA6JS4B7:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682747596","title":"Vivani Medical Announces Positive Top-Line Results from Slim-1™, a First in Human Phase 1 Trial of Npm-139 (Semaglutide Implant) and Wegovy (Weekly Semaglutide Injections) in Obese and Overweight Subjects","url":"https://stock-news.laohu8.com/highlight/detail?id=2682747596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682747596?lang=en_us&edition=fundamental","pubTime":"2026-11-12 21:00","pubTimestamp":1794488400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nTUA6JS4B7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682596720","title":"Vivani Medical - Npm-139 Maximum Drug Levels Reached at ~16 Days; Wegovy at ~2.4 Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2682596720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682596720?lang=en_us&edition=fundamental","pubTime":"2026-11-12 21:00","pubTimestamp":1794488400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nTUA6JS4B7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682596086","title":"Vivani Medical - no Serious Adverse Events Reported in Slim-1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2682596086","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682596086?lang=en_us&edition=fundamental","pubTime":"2026-11-12 21:00","pubTimestamp":1794488400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nTUA6JS4B7:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682596057","title":"Vivani Medical - Comparable Weight Loss Observed Between Npm-139 and Wegovy Groups","url":"https://stock-news.laohu8.com/highlight/detail?id=2682596057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682596057?lang=en_us&edition=fundamental","pubTime":"2026-11-12 21:00","pubTimestamp":1794488400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nTUA6JS4B7:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682587262","title":"Vivani Medical Inc Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2682587262","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682587262?lang=en_us&edition=fundamental","pubTime":"2026-11-12 05:35","pubTimestamp":1794432906,"startTime":"0","endTime":"0","summary":"Vivani Medical Inc reports results for the quarter ended September 30 - Earnings SummaryVivani Medical IncVANI.OQreported a quarterly adjusted loss of 8 cents per share for the quarter ended September","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261111:nL5N46S268:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682941587","title":"Vivani Medical Says Top-Line Results From Phase 1 SLIM-1 Trial of Semaglutide Implant Expected Later This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2682941587","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682941587?lang=en_us&edition=fundamental","pubTime":"2026-11-12 05:24","pubTimestamp":1794432273,"startTime":"0","endTime":"0","summary":"Vivani Medical Says Top-Line Results From Phase 1 SLIM-1 Trial of Semaglutide Implant Expected Later This Week","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/VANI","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682858762","title":"Weight-Loss Implant Developer Vivani Medical's Q3 Net Loss Widens on Higher Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2682858762","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682858762?lang=en_us&edition=fundamental","pubTime":"2026-11-12 05:24","pubTimestamp":1794432246,"startTime":"0","endTime":"0","summary":"Weight-loss implant developer Vivani Medical's Q3 net loss widens on higher costsOverviewUS drug-delivery implant maker's Q3 net loss widened yr/yr on higher R&D and admin costsCompany's cash and equi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261111:nL2N46S0XV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP","BK4082","CRGT","CAPR","VANI","TYRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682587945","title":"Vivani Medical Q3 EPS $(0.08), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2682587945","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682587945?lang=en_us&edition=fundamental","pubTime":"2026-11-12 05:24","pubTimestamp":1794432242,"startTime":"0","endTime":"0","summary":"Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 27.27 percent increase over losses of $(0.11) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/63169525/vivani-medical-q3-eps-0-08-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Vivani Medical Q3 EPS $(0.08), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682258735","title":"Vivani Medical Q3 EPS USD -0.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2682258735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682258735?lang=en_us&edition=fundamental","pubTime":"2026-11-12 05:15","pubTimestamp":1794431712,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261111:nPLXMSTTDL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682958271","title":"Vivani Medical Q3 Net Loss Widens 11% Year over Year to $7.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2682958271","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682958271?lang=en_us&edition=fundamental","pubTime":"2026-11-12 05:05","pubTimestamp":1794431157,"startTime":"0","endTime":"0","summary":"Vivani Medical Q3 net loss widens 11% year over year to $7.25 millionVivani Medical’s third-quarter 2026 net loss widened 11% year over year to $7.25 million.Research and development expense rose 11% ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261111:nNDL3ngSyJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00BQXX3C00.GBP","BCDF","SG9999014021.USD","VANI","CRGT","BK4082","SG9999014039.USD","SG9999014013.SGD","BK4588","SG9999014005.SGD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BQXX3F31.USD","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","NDAQ","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4112","IE00BQXX3D17.EUR","LU0314104364.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682582749","title":"Press Release: Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2682582749","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682582749?lang=en_us&edition=fundamental","pubTime":"2026-11-12 05:05","pubTimestamp":1794431100,"startTime":"0","endTime":"0","summary":"Top-line results for SLIM-1(TM), the first-in-human Phase 1 trial of NPM-139, Vivani's miniature, ultra-long-acting semaglutide implant under development for chronic weight management, are anticipated","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","TM","03160","BK4555","BK4585","VANI","BK4082","BK4588","R","CRGT","BK4232","BK4022","BK4099","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682738647","title":"Vivani Medical Inc Expected to Post a Loss of 8 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2682738647","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682738647?lang=en_us&edition=fundamental","pubTime":"2026-11-09 21:49","pubTimestamp":1794232148,"startTime":"0","endTime":"0","summary":"Vivani Medical Inc <VANI.OQ> expected to post a loss of8cents a share - Earnings PreviewVivani Medical IncVANI.OQVANI.Ois expected to  show no change in quarterly revenue when it reports  results on N","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261109:nL5N46Q1G9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679240810","title":"Vivani Says Cortigent-ClearOne Deal Awaits Final Regulatory Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2679240810","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679240810?lang=en_us&edition=fundamental","pubTime":"2026-10-31 04:31","pubTimestamp":1793392310,"startTime":"0","endTime":"0","summary":"Vivani Says Cortigent-ClearOne Deal Awaits Final Regulatory ApprovalVivani Medical's transaction to make its wholly owned Cortigent subsidiary a wholly owned subsidiary of ClearOne remains pending fin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261030:nNDLpQjW8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRO","BK4020","BK4082","VANI","CRGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679284559","title":"Vivani Medical Presents Development Plans for Once- or Twice-Yearly Semaglutide Implant","url":"https://stock-news.laohu8.com/highlight/detail?id=2679284559","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679284559?lang=en_us&edition=fundamental","pubTime":"2026-10-29 23:47","pubTimestamp":1793288820,"startTime":"0","endTime":"0","summary":"Vivani Medical Presents Development Plans for Once- or Twice-Yearly Semaglutide ImplantVivani Medical expects top-line results from its SLIM-1 Phase 1 trial of semaglutide implant NPM-139 in November ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nNDLfRblq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674187438","title":"Vivani Medical to Present at ThinkEquity Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2674187438","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674187438?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:00","pubTimestamp":1791802859,"startTime":"0","endTime":"0","summary":"Vivani Medical to present at ThinkEquity ConferenceVivani Medical will attend the Maxim Growth Summit on Oct. 14, 2026 in New York.Management will hold investor and partner meetings at the event.The c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nNDL2RZ0Kw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4112","SG9999014005.SGD","SG9999014021.USD","BK4585","NDAQ","IE00B64PRP62.GBP","LU2210150020.SGD","BK4082","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU0314104364.USD","VANI","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","SG9999014039.USD","BK4588","LU2095319765.USD","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668933216","title":"Vivani Medical Says Cortigent Merger with ClearOne Unit Expected to Price and Close in October 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2668933216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668933216?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:18","pubTimestamp":1789589899,"startTime":"0","endTime":"0","summary":"Vivani Medical says Cortigent merger with ClearOne unit expected to price and close in October 2026Vivani Medical entered a merger agreement to combine its unit Cortigent into ClearOne via a merger wi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL1bfywB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRO","BK4020","BK4082","VANI","CRGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660498488","title":"Analysts Offer Insights on Healthcare Companies: Vivani Medical (VANI) and InspireMD (NSPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660498488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660498488?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:00","pubTimestamp":1787061614,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vivani Medical (VANI) and InspireMD (NSPR) with bull...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vivani-medical-vani-and-inspiremd-nspr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vivani-medical-vani-and-inspiremd-nspr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4198","XLV","BK4585","LU0128526141.USD","BK4137","BK4581","HCSG","NSPR","LU0029874061.USD","BK4588","BK4082","XBI","LABU","VANI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vivani.com;investors.vivani.com","stockEarnings":[{"period":"1week","weight":-0.0544},{"period":"1month","weight":-0.1666},{"period":"3month","weight":-0.2976},{"period":"6month","weight":-0.1595},{"period":"1year","weight":-0.3573},{"period":"ytd","weight":-0.2005}],"compareEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0248},{"period":"6month","weight":0.0243},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.1103}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":-0.013761},{"month":2,"riseRate":0.333333,"avgChangeRate":0.262607},{"month":3,"riseRate":0.333333,"avgChangeRate":0.172227},{"month":4,"riseRate":0.416667,"avgChangeRate":0.031848},{"month":5,"riseRate":0.5,"avgChangeRate":0.041822},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.052506},{"month":7,"riseRate":0.5,"avgChangeRate":-0.01797},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.093324},{"month":9,"riseRate":0.583333,"avgChangeRate":-0.045145},{"month":10,"riseRate":0.25,"avgChangeRate":-0.078493},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.065609},{"month":12,"riseRate":0.333333,"avgChangeRate":0.011596}],"exchange":"NASDAQ","name":"Vivani Medical, Inc.","nameEN":"Vivani Medical, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vivani Medical, Inc.(VANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vivani Medical, Inc.(VANI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vivani Medical, Inc.,VANI,Vivani Medical, Inc.股票,Vivani Medical, Inc.股票老虎,Vivani Medical, Inc.股票老虎国际,Vivani Medical, Inc.行情,Vivani Medical, Inc.股票行情,Vivani Medical, Inc.股价,Vivani Medical, Inc.股市,Vivani Medical, Inc.股票价格,Vivani Medical, Inc.股票交易,Vivani Medical, Inc.股票购买,Vivani Medical, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vivani Medical, Inc.(VANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vivani Medical, Inc.(VANI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction